At Oncopeptides, we are advancing therapies for difficult-to-treat hematological diseases like multiple myeloma.
Oncopeptides’ lead candidate, melphalan flufenamide (also referred to as melflufen), is a first-in-class anti-cancer peptide-drug conjugate designed to rapidly deliver an alkylating payload into tumor cells. Melphalan flufenamide is an investigational drug and has not been approved by the FDA or any other regulatory agency.
With established North America operations based in San Francisco Bay Area, California and Waltham, Massachusetts, Oncopeptides is poised for continued growth in these global hubs of biotech pioneers, scientific exploration and technological innovation.
Connect with Oncopeptides directly by visiting our Contact page. Join the team: During this exciting period of growth, Oncopeptides is actively seeking bright, energetic candidates with health care or biopharmaceutical experience. Learn more and submit your resume at the Careers page.
Oncopeptides North America is a subsidiary of Oncopeptides AB (Nasdaq Stockholm: ONCO), headquartered in Stockholm, Sweden. The senior management currently consists of the CEO, CFO, Head of Regulatory Affairs, COO, Head of Research and CMC, CMO, CSO, CCO, President North America, General Counsel and Global Head of Corporate Communications. Please visit the Senior Management page to learn more.
Please visit our Media page to learn the latest on company announcements and breaking news.